Name of the presenter

Size: px
Start display at page:

Download "Name of the presenter"

Transcription

1 Progress in tuberculosis care: setting the scene for Central Asia Name of the presenter Gombogaram Tsogt, Shalva Gamtsemlidze Quality Health Care Project

2 Global TB estimates All forms of TB greatest number of cases in Asia greatest rates per capita in Africa MDR-TB Estimeted number of cases 9.27 million (139 per 100,000) 511,000 Estimated number of deaths 1.77 million (18%) (25 per 100,000) ~150,000 (29%) XDR-TB ~50,000 ~30,000 (60%) HIV-associated TB 1,4 Million (15%) 456,000

3 The greatest tragedy that can happen to a tuberculosis patient is that his tubercle bacilli become resistant to standard drugs" (Sir John Crofton, 1959) MDR-TB % among new cases, >10.00 No data MDR-TB % among new cases, * Sub-national coverage in India, China, Russia, Indonesia. The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ã WHO All rights reserved

4 World Health Day 2011

5 Why AMR is a global concern? Antimicrobial resistance (AMR) kills Challenges care and control of infectious diseases Greatly increases care costs Threatens a return to the pre-antibiotic era Jeopardizes healthcare gains for individuals and society Compromises health security, damages trade and economy Lack of coherent approaches to prevention and containment

6 What drives AMR? Role responsibilities of medical staff in providing multiple AB therapy Consumers, communities not sufficiently informed on the risks linked with misuse and overuse of AB Regulations on the sale of AB not enforced (over the counter sale) Surveillance systems weak or absent Systems for ensuring quality and supply of medicines inadequate, issue of counterfeit medicines Use of medicines inappropriate and irrational Infection prevention and control poor Antimicrobials and diagnostics arsenal limited Research and development for diagnostics and medicines insufficient

7 Treatment failure KAZ New SS KGZ New SS TJK New SS TKM New SS UZB New SS Retreatment Retreatment Retreatment Retreatment Retreatment

8 Treatment default KAZ New SS Relapse KGZ New SS Relapse TJK New SS Relapse TKM New SS Relapse UZB New SS Relapse

9 Fate of pulmonary TB SS+ patients who either did not receive treatment or had inadequate therapy 100 Chronic excretion of bacteria 80 percentage Negative results of bacteriological investigations 20 0 No intervention Inadequate intervention Died Grzybowski S, et al. Tubercle 1987;2(suppl):33-7

10 TB notification rates in CAR,

11 Plan «Stop TB» in Eastern Europe: implementation 99 countries reported treatment success rates 70% or over and DOTS detection rates 50% or over 32 countries (including 2 countries out of range of graph) have reached both targets.

12 WHA treatment success target reached in 2005 (globally) Percentage , million Europe: 71%, Africa: 76%, Americas: 78%

13 MDR-TB rate (%), Country Among new cases>12% Among retreatment cases>50% Azerbaijan, Baku Estonia 15.4 Kazakhstan Latvia 12.1 Republic of Moldova Russian Federation: Mari El and Tomsk Obl & 15.0 Ivanovo Obl Tajikistan, Dushanbe and Rudaki Ukraine (Donetsk Obl.) 16.0 Uzbekistan Karakalpakstan and Tashkent 13.2 & 14.8

14 KAZAKHSTAN By number of patients (world) 33 (213 countries) In European Region 4 (53 countries) MDR-TB prevalence 3 Treatment success 64% Incidence (per ) Prevalence (per ) Mortality (per ) MDR-TB Number of MDR-TB cases, new Number of MDR-TB cases, retreatment Total number of MDR-TB cases to be detected through laboratory investigations 6,051 8,471 6,401 5,689 5,784 6,043 6,068 5,893 5,860

15 KYRGYZSTAN By number of patients (world) 72 (213 countries) In European Region 10 (53 countries) MDR-TB prevalence 9 Treatment success 84% Incidence (per ) Prevalence (per ) Mortality (per ) MDR-TB Estimated number of MDR-TB cases Number of patients enrolled on treatment (16% of new cases and 61% of retreatment cases) % of patients enrolled on treatment out of estimated number of patients

16 TURKMENISTAN By number of patients (world) 99 (213 countries) In European Region 21 (53 countries) MDR-TB prevalence 0 Treatment success 83% Incidence (per ) 65,5 61,5 Prevalence (per ) 216,9 211,1 Mortality (per ) 7,3 6,5 MDR-TB Estimated number of MDR-TB patients Number of MDR-TB patients planned to be treated through the GF funding % out of total estimated number of MDR-TB patients

17 TAJIKISTAN By number of patients (world) 76 (213 countries) In European Region 13 (53 countries) MDR-TB prevalence 7 Treatment success 82% Incidence (per ) 83,8 78,7 Prevalence (per ) 205,1 195,2 Mortality (per ) 5,4 5,9 MDR-TB Estimated number of MDR-TB patients Number of MDR-TB patients planned to be treated Number of MDR-TB patients planned to be treated through the GF funding % out of total estimated number of MDR-TB patients

18 UZBEKISTAN By number of patients (world) 36 (213 countries) In European Region 5 (53 countries) MDR-TB prevalence 4 Treatment success 81% MDR-TB Incidence (per ) Prevalence (per ) Mortality (per ) Estimated number of MDR-TB cases, new Estimated number of MDR-TB cases, retreatment Number of MDR-TB patients planned to be treated

19 Cost of activities, 2011* (USD) Cost The world, excluding Eastern Europe Eastern Europe DOTS treatment (per patient) 382 ( ) 5,840 (5,640 6,190) MDR-TB treatment (per patient) 3,320 8,860 MDR-TB diagnosis (per lab test) Drug susceptibility test for SLD 118 ART (per patient, 6 months) 522 HIV test (per person) 9 14 Co-trimoxazole preventive therapy (per person) 4.7 *Cost increases by 3% per year due to inflation

20 TB Control Global Targets 2015: Goal 6: Combat HIV/AIDS, malaria and other diseases Target 6.c: to have halted by 2015 and begun to reverse the incidence Indicator 6.9: incidence, prevalence and deaths associated with TB Indicator 6.10: proportion of TB cases detected and cured under DOTS 2015: 50% reduction in TB prevalence (65/100,000 in 2004) and deaths (8/100,000 in 2004) compared with their levels in : elimination (<1 case per million population)

21 THE STOP TB STRATEGY

22 COMPONENTS OF STOP TB STRATEGY 2. Address TB/HIV, MDR-TB and other challenges Implement collaborative TB/HIV activities Prevent and control MDR-TB Address prisoners, refugees and other high-risk groups and situations

23 Drug resistance and tuberculosis control Be aware of resistance problem Surveillance Resolve resistance problem Treatment with SLDs Prevent resistance problem Adequate treatment (in line with standards)

24 Treatment duration of sensitive and resistant tuberculosis TB 6 months MDR-TB 4 drugs Treatment success up to 95%, side effects 2% MDR-TB 24 months XDR-TB 6-7 drugs Treatment success up to 70-75%, side effects up to 20%

25 Will a physician be able to cure a patient using SLDs if he could not achieve cure through DOTS? Will a patient be able to complete a treatment course with SLDs if he could not complete DOTS treatment? If Yes, what needs to be changed?

26 If you miss the first buttonhole, you can t ever get fully buttoned up Johann Wolfgang von Goethe

27 Найди ТБ Излечи ТБ

The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps

The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps Matteo Zignol STOP TB Department World Health Organization TB surveillance and

More information

The epidemiology of tuberculosis

The epidemiology of tuberculosis The epidemiology of tuberculosis Tuberculosis Workshop Shanghai, 12-22 May 28 Philippe Glaziou World Health Organization Outline Epidemiology refresher Estimates of tuberculosis disease burden Notifications

More information

Progress on the targets of Millennium Development Goal 6 in central and eastern Europe and central Asia

Progress on the targets of Millennium Development Goal 6 in central and eastern Europe and central Asia Progress on the targets of Millennium Development Goal 6 in central and eastern Europe and central Asia 11 October 2011 Moscow, Russian Federation Zsuzsanna Jakab WHO Regional Director for Europe Millennium

More information

TB/HIV in the WHO European Region Overview, Priorities & Response

TB/HIV in the WHO European Region Overview, Priorities & Response TB/HIV in the WHO European Region Overview, Priorities & Response 16 th Core Group Meeting TB/HIV Working Group Stop TB Partnership Almaty, Kazakhstan May 2010 Martin Donoghoe Andrei Dadu, Smiljka de Lussigny

More information

What can be done against XDR-TB?

What can be done against XDR-TB? What can be done against XDR-TB? Dr Matteo Zignol Stop TB Dep. World Health Organization Geneva 16 th Swiss Symposium on tuberculosis Münchenwiler, 22 March 2007 XDR-TB Extensive Drug Resistance XDR =

More information

Epidemiological trends of TB in Eastern Europe TB and migration

Epidemiological trends of TB in Eastern Europe TB and migration KOCH-METSCHNIKOW-FORUM МEЧНИКОВ-КОХ-ФОРУМ XX Congreso Internacional sobre Tuberculosis UITB-216 November 21 and 22, 216 Epidemiological trends of TB in Eastern Europe TB and migration Timo Ulrichs Koch-Metschnikow-Forum,

More information

Drug resistance TB in People Living with HIV: research questions and priorities.

Drug resistance TB in People Living with HIV: research questions and priorities. Drug resistance TB in People Living with HIV: research questions and priorities. Haileyesus Getahun, MD, PhD. Stop TB Department World Health Organisation Geneva, Switzerland Outline of presentation Definition

More information

511,000 (57% new cases) ~50,000 ~30,000

511,000 (57% new cases) ~50,000 ~30,000 Latest global TB estimates - 2007 (Updated Mar 2009) All forms of TB Greatest number of cases in Asia; greatest rates per capita in Africa Multidrug-resistant TB (MDR-TB) Estimated number of cases 9.27

More information

3.1 PHASE 2 OF THE GLOBAL PROJECT

3.1 PHASE 2 OF THE GLOBAL PROJECT RESULTS CHAPTER 3 3.1 PHASE 2 OF THE GLOBAL PROJECT (1996 1999) This new report of the Global Project provides data on anti-tuberculosis drug resistance from 58 geographical settings. Of these, 28 provided

More information

XDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps

XDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever

More information

2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges

2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges Outline of what it will take Tuberculosis Elimination 25: Global and Local Challenges Anne Fanning, MD November 9, 211 21 global TB trends, goals How DOTS happens at country level - an exercise New strategies

More information

Stop TB Working Group on DOTS-Plus for MDR-TB Strategic Plan

Stop TB Working Group on DOTS-Plus for MDR-TB Strategic Plan Stop TB Working Group on DOTS-Plus for MDR-TB Strategic Plan 2006-2015 Background Current threat and status of the global epidemic of multidrug resistant tuberculosis (MDR-TB) Along with HIV/AIDS, MDR-TB

More information

Multidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017

Multidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017 Multidrug-/ rifampicinresistant TB (MDR/RR-TB): Update 2017 The global TB situation (1) Estimated incidence, 2016 Estimated number of deaths, 2016 All forms of TB HIV-associated TB Multidrug- / rifampicin-resistant

More information

CANCER FACT SHEETS: BREAST CANCER

CANCER FACT SHEETS: BREAST CANCER CANCER FACT SHEETS: BREAST CANCER Estimated age-standardised rates (World) in the world (per 100 000) At a glance WHO South-East Asia Region More developed regions WHO African Region WHO Region of the

More information

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB Sindy M. Paul, MD, MPH, FACPM May 1, 2012 The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB morbidity, including resistance Identifying people

More information

XDR and MDR TB Urgent Research Priorities. Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine

XDR and MDR TB Urgent Research Priorities. Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine XDR and MDR TB Urgent Research Priorities Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine The Year of MDR XDR TB CDC, WHO report on global XDR TB XDR TB defined Global distribution

More information

Global, National, Regional

Global, National, Regional Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology

More information

World Health Organization 2013

World Health Organization 2013 World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization,

More information

XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS. Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma. Pag. 1

XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS. Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma. Pag. 1 XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma Pag. 1 TB estimated incidence in EUR, 2004 Russian Fed. 12 th among the 22 TB high-burden

More information

Global, National, Regional

Global, National, Regional Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology

More information

Antimicrobial resistance Fact sheet N 194 Updated April 2014

Antimicrobial resistance Fact sheet N 194 Updated April 2014 Antimicrobial resistance Fact sheet N 194 Updated April 2014 Key facts Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by

More information

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition

More information

Controlling TB in the era of HIV

Controlling TB in the era of HIV Controlling TB in the era of HIV Christy Hanson, PhD, MPH TB Research Advisor Amy Bloom, MD TB/HIV Advisor TB Incidence rates highest in Africa Estimated new TB cases (all forms) per 100 000 population

More information

CANCER FACT SHEETS: ALL CANCERS EXCLUDING NON-MELANOMA SKIN CANCER

CANCER FACT SHEETS: ALL CANCERS EXCLUDING NON-MELANOMA SKIN CANCER CANCER FACT SHEETS: ALL CANCERS EXCLUDING NON-MELANOMA SKIN CANCER Estimated age-standardised rates (World) in the world (per 100 000) At a glance United States of America European Union (EU-28) More developed

More information

Tuberculosis surveillance in Germany. Data of the tuberculosis report 2013

Tuberculosis surveillance in Germany. Data of the tuberculosis report 2013 1 Tuberculosis surveillance in Germany Data of the tuberculosis report 2013 Robert Koch Institute (RKI) Respiratory Infections Unit Outline 2 Tuberculosis notification system in Germany Epidemiological

More information

Reflecting on ten years of progress in the fight against AIDS, TB and malaria

Reflecting on ten years of progress in the fight against AIDS, TB and malaria Reflecting on ten years of progress in the fight against AIDS, TB and malaria Michel Kazatchkine UN Secretary General s Special Envoy on HIV/AIDS in Eastern Europe and central Asia Ten years of progress:

More information

2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:

2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services: The theme for World TB Day 2014 is Reach the missed 3 million. Every year 3 million people who fall ill with TB are missed by health systems and do not always get the TB services that they need and deserve.

More information

The WHO END-TB Strategy

The WHO END-TB Strategy ENDING TB and MDR-TB The WHO END-TB Strategy Dr Mario RAVIGLIONE Director Joint GDI/GLI Partners Forum WHO Geneva, 27 April 2015 This talk will deal with TB Burden Progress, Challenges Way Forward Who

More information

CANCER FACT SHEETS: STOMACH CANCER

CANCER FACT SHEETS: STOMACH CANCER CANCER FACT SHEETS: STOMACH CANCER Estimated age-standardised rates (World) in the world (per 100 000) At a glance WHO Western Pacific Region China Less developed regions World More developed regions IARC

More information

SUPERBUGS THE ROLE OF DIAGNOSTICS EXPLAINED

SUPERBUGS THE ROLE OF DIAGNOSTICS EXPLAINED & SUPERBUGS THE ROLE OF DIAGNOSTICS EXPLAINED 1 of 17 Superbugs are microorganisms resistant to drugs that were previously effective. Before resistance After resistance 2 of 17 WHAT S MAKING THE PROBLEM

More information

Key issues for HIV testing and

Key issues for HIV testing and Key issues for HIV testing and counselling in Europe Martin C Donoghoe Programme Manager HIV/AIDS, STI &Viral Hepatitis Programme WHO Europe Key issues for HIV testing & counselling in Europe HIV epidemics

More information

CANCER FACT SHEETS: LIVER CANCER

CANCER FACT SHEETS: LIVER CANCER CANCER FACT SHEETS: LIVER CANCER Estimated age-standardised rates (World) in the world (per 100 000) At a glance China WHO Western Pacific Region Less developed regions World WHO African Region United

More information

Tuberculosis: Opportunities and Challenges for Achieving HIV Epidemic Control

Tuberculosis: Opportunities and Challenges for Achieving HIV Epidemic Control Tuberculosis: Opportunities and Challenges for Achieving HIV Epidemic Control Suvanand Sahu Deputy Executive Director Stop TB Partnership Secretariat Tuberculosis TB epidemic is declining very slowly We

More information

HIV and Hepatitis Prevention Programmes in Eastern Europe Case Example: Georgia

HIV and Hepatitis Prevention Programmes in Eastern Europe Case Example: Georgia HIV and Hepatitis Prevention Programmes in Eastern Europe Case Example: Georgia Nikoloz Chkhartishvili, MD, MS, PhD Deputy Executive Director for Research Infectious Diseases, AIDS and Clinical Immunology

More information

Measuring TB burden and access to TB services for people who inject drugs in the WHO European Region, 2010 and 2011

Measuring TB burden and access to TB services for people who inject drugs in the WHO European Region, 2010 and 2011 Measuring TB burden and access to TB services for people who inject drugs in the WHO European Region, 2010 and 2011 Annabel Baddeley Global TB Programme WHO, Geneva Outline of presentation Global and European

More information

#4 (Tuberculosis OR TB OR Pulmonary Tuberculosis OR Multi-Drug Resistant Tuberculosis OR MDR OR Extremely-Drug Resistant Tuberculosis or XDR)

#4 (Tuberculosis OR TB OR Pulmonary Tuberculosis OR Multi-Drug Resistant Tuberculosis OR MDR OR Extremely-Drug Resistant Tuberculosis or XDR) DATABASE Cochrane Database of Systematic Reviews DATE 15 DECEMBER 2015 #1 Safety of Crucell Ad35/ AERAS-402 OR Effectiveness of Crucell Ad35/ Aeras-402 OR Safety of MVA85A/ Aeras-485 OR Effectiveness of

More information

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific Health System Strengthening and Sustaining the Response The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific Jintana Ngamvithayapong-Yanai, Ph.D. On behalf of TB/HIV Working Group, the

More information

May 26-28, 2010, Almaty, Kazakhstan November 2011

May 26-28, 2010, Almaty, Kazakhstan November 2011 Progress note of the recommendations of the 16 th TB/HIV Core Group Meeting Report May 26-28, 2010, Almaty, Kazakhstan November 2011 1. Structural and organizational barriers The Core Group urges Ministries

More information

Combating HIV/AIDS and TB in Eastern Europe and Central Asia: The World Bank Response

Combating HIV/AIDS and TB in Eastern Europe and Central Asia: The World Bank Response Combating HIV/AIDS and TB in Eastern Europe and Central Asia: The World Bank Response Paolo Carlo Belli, Country Sector Coordinator, Human Development ECA Region May 13, 2011 November 28, 2007 ECA AIDS

More information

Childhood TB and new TB drugs in the WHO European Region

Childhood TB and new TB drugs in the WHO European Region Andrei Dadu Carl Cordonnier Maxim Dondiuk Childhood TB and new TB drugs in the WHO European Region Kigali, Rwanda, 09/10/ 2017 Dr Martin van den Boom, MD, MSc PH, WHO Regional Office for Europe, Joint

More information

HIV/AIDS IN EASTERN EUROPE AND CENTRAL ASIA (EECA) Charles Ssonko HIV/TB/Hepatitis Adviser Medecins Sans Frontieres

HIV/AIDS IN EASTERN EUROPE AND CENTRAL ASIA (EECA) Charles Ssonko HIV/TB/Hepatitis Adviser Medecins Sans Frontieres HIV/AIDS IN EASTERN EUROPE AND CENTRAL ASIA (EECA) Charles Ssonko HIV/TB/Hepatitis Adviser Medecins Sans Frontieres Objectives The Epidemiology of HIV/AIDS in the EECA Region (Trends) o The Burden of HIV/AIDS

More information

WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA

WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA September 2017 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe Marmorvej

More information

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific Health System Strengthening and Sustaining the Response The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific Jintana Ngamvithayapong-Yanai, Ph.D. On behalf of TB/HIV Working Group, the

More information

2009 Report. Tuberculosis Control. in the Western Pacific Region

2009 Report. Tuberculosis Control. in the Western Pacific Region 2009 Report Tuberculosis Control in the Western Pacific Region Prepared by Dr Angelito Bravo was the lead author of this report. The following WHO staff from the regional and the country offices contributed

More information

RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE WINTER SEASON

RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE WINTER SEASON RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE 2018 2019 WINTER SEASON October 2018 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for

More information

26 28 May 2010, Almaty, Kazkhstan. Nina Kerimi UNODC Regional Project Coordinator 1

26 28 May 2010, Almaty, Kazkhstan. Nina Kerimi UNODC Regional Project Coordinator 1 The 16 th Core Group Meeting of the TB/HIV Working Group 26 28 May 2010, Almaty, Kazkhstan Nina Kerimi UNODC Regional Project Coordinator 1 UNODC Regional Office for Central Asia covers 6 countries: AZE,

More information

THE Price of a Pandemic 2017

THE Price of a Pandemic 2017 THE Price of a Pandemic 2017 From 2000-2015: 33 million people died because of TB at a global economic cost of $617bn This report was produced the Global TB Caucus, an international network of over 2,000

More information

C R E A E. Consortium to Respond Effectively to the AIDS-TB Epidemic. An International Research Partnership

C R E A E. Consortium to Respond Effectively to the AIDS-TB Epidemic. An International Research Partnership C R E A E Consortium to Respond Effectively to the AIDS-TB Epidemic An International Research Partnership Supported by the Bill and Melinda Gates Foundation http://www.tbhiv-create.org Overview What is

More information

La Lotta alla Tubercolosi. Matteo Zignol and Mario C. Raviglione Stop TB Department WHO, Geneva, Switzerland. Geneva March 2012

La Lotta alla Tubercolosi. Matteo Zignol and Mario C. Raviglione Stop TB Department WHO, Geneva, Switzerland. Geneva March 2012 La Lotta alla Tubercolosi Matteo Zignol and Mario C. Raviglione Stop TB Department WHO, Geneva, Switzerland Geneva 19-20 March 2012 Overview of the presentation The global burden of tuberculosis The WHO

More information

How Is TB Transmitted? Sébastien Gagneux, PhD 20 th March, 2008

How Is TB Transmitted? Sébastien Gagneux, PhD 20 th March, 2008 How Is TB Transmitted? Sébastien Gagneux, PhD 20 th March, 2008 Today s Outline 1) Global spread of Mtb Comparative genomics Phylogeny 2) Transmission of drug-resistant Mtb Fitness assays Molecular epidemiology

More information

MDR-TB and HIV co-infection in Eastern Europe. Francis Drobniewski MBBS PhD Professor of Global Health and Tuberculosis

MDR-TB and HIV co-infection in Eastern Europe. Francis Drobniewski MBBS PhD Professor of Global Health and Tuberculosis MDR-TB and HIV co-infection in Eastern Europe Francis Drobniewski MBBS PhD Professor of Global Health and Tuberculosis f.drobniewski@imperial.ac.uk Conflict of interest In the last year I have been a consultant

More information

Problems of MDR-TB in Russia

Problems of MDR-TB in Russia Problems of MDR-TB in Russia Vladislav V. Erokhin Director Central TB Research Institute Russian Academy of Medical Science Tbilisi, September 2007 In 2006: 24055 (20.3%) MDR-TB cases registered in Russia

More information

TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION In the WHO Western Pacific Region 2002 Report

TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION In the WHO Western Pacific Region 2002 Report TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION 2000 Tuberculosis Control In the WHO Western Pacific Region 2002 Report World Health Organization Office for the Western Pacific Region iii TUBERCULOSIS

More information

Epidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur

Epidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur Epidemiology of Hepatitis B in sub-saharan Africa 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur From the Big Three to the Big Four 1600000 Number of deaths/year 1400000 HAV + HEV 1200000 1000000

More information

Technology and innovation: Changing dynamics of TB control. Karin Weyer

Technology and innovation: Changing dynamics of TB control. Karin Weyer Technology and innovation: Changing dynamics of TB control Karin Weyer Latest news 1. New tools finally a reality 2. Universal access for all affected from TB 3. Emphasis on early case detection and treatment

More information

Using Data For Decision Making

Using Data For Decision Making Using Data For Decision Making Juliana Víctor-Ahuchogu World Bank Acknowledgment and data sources AIDS in the Commonwealth of Independent States: AIDS 2008 MAP Report: Magomed Nashkhoev & Boris Sergeyev,

More information

Vol. 5, No. 20 Fall 2010

Vol. 5, No. 20 Fall 2010 Vol. 5, No. 20 Fall 2010 IN THIS ISSUE: Snapshot Knowledge Hub activities to date, in numbers Knowledge Hub Calendar Find out about training workshops and other upcoming events Knowledge Hub in Review

More information

TB epidemic and progress towards the Millennium Development Goals

TB epidemic and progress towards the Millennium Development Goals Open Forum 4: Key issues in TB Drug Development, August 18, 2010, Addis Ababa, Ethiopia TB epidemic and progress towards the Millennium Development Goals Haileyesus Getahun Stop TB Department, WHO Geneva,

More information

VPD in Mediterranean Basin and Black Sea: the Polio case

VPD in Mediterranean Basin and Black Sea: the Polio case Screening practices for infectious diseases among newly arrived migrants and Vaccine Preventable Disease (VPD): strategies and coverage ISS 29 MAY 2015 VPD in Mediterranean Basin and Black Sea: the Polio

More information

The Global Fund s view on transition Dumitru Laticevschi The Global Fund

The Global Fund s view on transition Dumitru Laticevschi The Global Fund Treating Patient, Not Disease: People-Centered Approach 7th TB Symposium Ministry of Health of the Kyrgyz Republic and Médecins Sans Frontières 1-2 March, 2018, BISHKEK, KYRGYZSTAN The Global Fund s view

More information

Population. B.4. Malaria and tuberculosis

Population. B.4. Malaria and tuberculosis Statistical Yearbook for Asia and the Pacific 2013 B. Health B.4. Malaria and tuberculosis Malaria and tuberculosis (TB) are two infectious and potentially lethal diseases that have greatly affected the

More information

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL THESIS ABSTRACT

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL THESIS ABSTRACT UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL THESIS ABSTRACT Epidemiological aspects of tuberculosis disease in disadvantaged population groups in Dolj county in the period 2006-2011 PhD Supervisor,

More information

Market Updates: Routine Vaccine Introductions IPV. Vaccine Industry Consultation October 2018 UNICEF Supply Division

Market Updates: Routine Vaccine Introductions IPV. Vaccine Industry Consultation October 2018 UNICEF Supply Division Market Updates: Routine Vaccine Introductions IPV Vaccine Industry Consultation October 2018 UNICEF Supply Division Outline Review of rapid introduction of IPV Overview of the current situation for 2018

More information

Drug-resistant Tuberculosis

Drug-resistant Tuberculosis page 1/15 Scientific Facts on Drug-resistant Tuberculosis Source document: WHO (2008) Summary & Details: GreenFacts Level 2 - Details on Drug-resistant Tuberculosis 1. What is tuberculosis and why is it

More information

Christian Gunneberg MO WHO The 14th Core Group Meeting of the TB/HIV Working Group November 11-12, 2008, Addis Ababa, Ethiopia

Christian Gunneberg MO WHO The 14th Core Group Meeting of the TB/HIV Working Group November 11-12, 2008, Addis Ababa, Ethiopia The revised TB/HIV indicators and update on the process of harmonization Christian Gunneberg MO WHO The 14th Core Group Meeting of the TB/HIV Working Group November 11-12, 2008, Addis Ababa, Ethiopia Monitoring

More information

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye Director of Health Information World Health Organization Geneva 1 1. Why TB patients are treated with drugs 2 Natural history and control of TB Fast 5/1 Slow 5/1 Uninfected Latent Active 1 1 infection/case

More information

Implementing TB/HIV collaborative activities in prison settings: where are we?

Implementing TB/HIV collaborative activities in prison settings: where are we? Implementing TB/HIV collaborative activities in prison settings: where are we? Severin Lilian (1), Morosan Vitali (1), Doltu Svetlana (2), Ilona Burduja (2), Viorel Soltan (3), Sain Dmitri (4) (1)Carlux

More information

Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs

Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs What causes TB? TB is caused by the bacterium Mycobacterium tuberculosis. Although it can cause disease in

More information

The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America

The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America Mike Segar / Reuters Executive Summary Context On 26 September 2018, the United Nations

More information

THE FEW REMAINING (IMPOSSIBLE) CASES

THE FEW REMAINING (IMPOSSIBLE) CASES THE FEW REMAINING (IMPOSSIBLE) CASES AG Holley 60 th Anniversary Celebration AG Holley State Hospital Lantana, FL July 21, 2010 Lee B. Reichman, MD, MPH AG Holley 60th Anniversary Celebration 1 TB Historical

More information

Estimating the global burden of tuberculosis. WHO estimates of TB incidence, prevalence and mortality, by country,

Estimating the global burden of tuberculosis. WHO estimates of TB incidence, prevalence and mortality, by country, Estimating the global burden of tuberculosis WHO estimates of TB incidence, prevalence and mortality, by country, 1990 2007 This morning s presentation Why estimate the burden? A brief history of TB estimates

More information

The State of Measles and Rubella in the WHO European Region

The State of Measles and Rubella in the WHO European Region The State of Measles and Rubella in the WHO European Region Mark Muscat Vaccine-preventable Diseases and Immunization Rome, Italy, 16-17 June 2016 All six WHO Regions have measles elimination goals 2 Annual

More information

TB EPIDEMIOLOGY: IMPACT ON CHILDREN. Anneke C. Hesseling Desmond Tutu TB Centre Department Paediatrics and Child Health Stellenbosch University

TB EPIDEMIOLOGY: IMPACT ON CHILDREN. Anneke C. Hesseling Desmond Tutu TB Centre Department Paediatrics and Child Health Stellenbosch University TB EPIDEMIOLOGY: IMPACT ON CHILDREN Anneke C. Hesseling Desmond Tutu TB Centre Department Paediatrics and Child Health Stellenbosch University Robert Koch 1843-1910 Discovered M. tuberculosis 1882 TB deaths

More information

Measles and Rubella Global Update SAGE April 2018

Measles and Rubella Global Update SAGE April 2018 Measles and Rubella Global Update SAGE April 2018 Alya Dabbagh WHO HQ, IVB/EPI Overview Global update Regional update Surveillance overview M&RI Midterm Review updates Conclusions 2 Measles and Rubella

More information

Acknowledgements. Wild birds and the risk of a pandemic. Overview of the presentation

Acknowledgements. Wild birds and the risk of a pandemic. Overview of the presentation Wild birds and the risk of a pandemic FAO/OIE International Scientific Conference on Avian Influenza and Wild Birds Rome, 31 May, 2006 Caroline S. Brown Technical Officer, Communicable Diseases Surveillance

More information

with these FACTS... 2

with these FACTS... 2 Gibson Kibiki MD, MMed, PhD KCRI - KCMC Tanzania PRIOR 10 th Nov 2009, Nijmegen, The Netherlands 1 with these FACTS... 2 The leading causes of death worldwide from preventable infectious diseases 3.0 in

More information

GAVI in the WHO European Region: results, current status and future

GAVI in the WHO European Region: results, current status and future Strengthening immunization services and introduction of hepatitis B vaccine in countries of Central and Eastern Europe and Newly Independent States, 3 rd meeting, Кiev, 25-28 May 2004 GAVI in the WHO European

More information

A Review of the Sutezolid (PNU ) Patent Landscape

A Review of the Sutezolid (PNU ) Patent Landscape 2014 A Review of the Sutezolid (PNU-100480) Patent Landscape A scoping report JANUARY 2014 A Review of the Sutezolid (PNU-100480) Patent Landscape UNITAID Secretariat World Health Organization Avenue Appia

More information

Vol. 5, No. 18 Spring 2010

Vol. 5, No. 18 Spring 2010 Vol. 5, No. 18 Spring 2010 IN THIS ISSUE: Snapshot Knowledge Hub activities to date, in numbers Knowledge Hub Calendar Find out about training workshops and other upcoming events Knowledge Hub in Review

More information

Multidrug-resistant tuberculosis around the world: what progress has been made?

Multidrug-resistant tuberculosis around the world: what progress has been made? ORIGINAL ARTICLE TUBERCULOSIS Multidrug-resistant tuberculosis around the world: what progress has been made? Dennis Falzon, Fuad Mirzayev, Fraser Wares, Inés Garcia Baena, Matteo Zignol, Nguyen Linh,

More information

Fact sheets on sustainable development goals: health targets. Malaria

Fact sheets on sustainable development goals: health targets. Malaria SDG target 3.3: by 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, waterborne diseases and other communicable diseases. Fact sheets on sustainable

More information

GLOBAL TUBERCULOSIS REPORT EXECUTIVE SUMMARY

GLOBAL TUBERCULOSIS REPORT EXECUTIVE SUMMARY GLOBAL TUBERCULOSIS REPORT EXECUTIVE SUMMARY 2018 Context On 26 September 2018, the United Nations (UN) will hold its first highlevel meeting on tuberculosis (TB), at its headquarters in New York. The

More information

Principle of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos

Principle of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos Principle of Tuberculosis Control CHIANG Chen-Yuan MD, MPH, DrPhilos Estimated global tuberculosis burden 2015 an estimated 10.4 million incident cases of TB (range, 8.7 million 12.2 million) 142 cases

More information

GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy

GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA The critical need to scale up opioid substitution therapy Craig McClure IAS Executive Director Outline of Presentation 1.

More information

Vol. 6, No. 21 Winter

Vol. 6, No. 21 Winter Vol. 6, No. 21 Winter 2010-2011 IN THIS ISSUE: Snapshot Knowledge Hub activities to date, in numbers Knowledge Hub Calendar Find out about training workshops and other upcoming events Knowledge Hub in

More information

Updates on the global TB Global TB burden Policy response Treatment approaches

Updates on the global TB Global TB burden Policy response Treatment approaches Ernesto Updates on the global TB Global TB burden Policy response Treatment approaches Ernesto Jaramillo WHO Global TB Programmme World Health Organization, Geneva, Tuberculosis is the leading infectious

More information

TB in the SEA Region. Review Plans and Progress. Dr Md Khurshid Alam Hyder Medical Officer TB SEARO/WHO

TB in the SEA Region. Review Plans and Progress. Dr Md Khurshid Alam Hyder Medical Officer TB SEARO/WHO TB in the SEA Region Review Plans and Progress Dr Md Khurshid Alam Hyder Medical Officer TB SEARO/WHO The SEA Region: 25% of the world s people, but >33% of TB patients Eastern M editerranean Region 5%

More information

TB surveillance. Philippe Glaziou Dubrovnik, May 2009

TB surveillance. Philippe Glaziou Dubrovnik, May 2009 TB surveillance Philippe Glaziou Dubrovnik, May 2009 What are the global TB targets? Outcome targets (World Health Assembly, STB Partnership) Case detection ratio > 70% Treatment success > 85% 2015 Impact

More information

A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%

A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10% % of reported measles cases WHO EpiBrief A report on the epidemiology of selected vaccine-preventable diseases in the European Region No. /17 This issue of WHO EpiBrief provides an overview of selected

More information

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE) TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global

More information

Vaccine Preventable Disease Surveillance: Overview. Thomas Cherian, WHO

Vaccine Preventable Disease Surveillance: Overview. Thomas Cherian, WHO Vaccine Preventable Disease Surveillance: Overview Thomas Cherian, WHO Global Framework on Immunization Monitoring and Surveillance (GFIMS) l An extension of the GIVS, published on December 07 - http://www.who.int/immunization/en/

More information

HIV as a Risk Factor for TB Henry Pacheco, MD November 13, 2008

HIV as a Risk Factor for TB Henry Pacheco, MD November 13, 2008 Tuberculosis Updates for Clinicians San Antonio, Texas November 13, 2008 HIV as a Risk Factor for TB Henry Pacheco, MD November 13, 2008 HIV as a Risk Factor for TB Tuberculosis Update for the Clinician

More information

Progress in Flour Fortification in Central and Eastern Europe and Commonwealth of Independent States

Progress in Flour Fortification in Central and Eastern Europe and Commonwealth of Independent States Progress in Flour Fortification in Central and Eastern Europe and Commonwealth of Independent States Vilma Q. Tyler UNICEF CEE/CIS Regional Nutrition Specialist Ankara, 12-15 June, 2012 Factors Impacting

More information

Drug-resistant Tuberculosis

Drug-resistant Tuberculosis page 1/6 Scientific Facts on Drug-resistant Tuberculosis Source document: WHO (2008) Summary & Details: GreenFacts Context - Tuberculosis (TB) is an infectious disease that affects a growing number of

More information

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe

More information

Measles and Rubella Global Update SAGE 19 October 2017

Measles and Rubella Global Update SAGE 19 October 2017 Measles and Rubella Global Update SAGE 19 October 2017 Alya Dabbagh WHO HQ, IVB/EPI Global update Overview Regional progress and challenges M&RI Midterm Review updates Economics of measles and rubella

More information

Alcohol-related harm in Europe and the WHO policy response

Alcohol-related harm in Europe and the WHO policy response Alcohol-related harm in Europe and the WHO policy response Lars Moller Programme Manager World Health Organization Regional Office for Europe Date of presentation NCD global monitoring framework: alcohol-related

More information

DRUG-RESISTANT TB SURVEILLANCE & RESPONSE SUPPLEMENT GLOBAL TUBERCULOSIS REPORT 2014

DRUG-RESISTANT TB SURVEILLANCE & RESPONSE SUPPLEMENT GLOBAL TUBERCULOSIS REPORT 2014 DRUG-RESISTANT TB SURVEILLANCE & RESPONSE SUPPLEMENT GLOBAL TUBERCULOSIS REPORT 2014 World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the

More information

Need for Chronic Viral Hepatitis Monitoring System

Need for Chronic Viral Hepatitis Monitoring System Need for Chronic Viral Hepatitis Monitoring System Harry L.A. Janssen Dept. of Gastroenterology & Hepatology Erasmus University Medical Center Rotterdam The Netherlands Rotterdam November 2008 National

More information

CHAIR: DR JORGE SAMPAIO, UN SECRETARY-GENERAL'S SPECIAL ENVOY TO STOP TB AND FORMER PRESIDENT OF THE PORTUGUESE REPUBLIC

CHAIR: DR JORGE SAMPAIO, UN SECRETARY-GENERAL'S SPECIAL ENVOY TO STOP TB AND FORMER PRESIDENT OF THE PORTUGUESE REPUBLIC PROVISIONAL AGENDA WEDNESDAY 1 APRIL 2009 SESSION 1: THE CHALLENGE OF M/XDR-TB: GLOBAL AND NATIONAL LEADERSHIP CHAIR: DR JORGE SAMPAIO, UN SECRETARY-GENERAL'S SPECIAL ENVOY TO STOP TB AND FORMER PRESIDENT

More information